Cargando…
Simultaneous Tumor and Stroma Targeting by Oncolytic Viruses
Current cancer therapeutics often insufficiently eradicate malignant cells due to the surrounding dense tumor stroma. This multi-componential tissue consists of mainly cancer-associated fibroblasts, the (compact) extracellular matrix, tumor vasculature, and tumor-associated macrophages, which all ex...
Autores principales: | Everts, Anne, Bergeman, Melissa, McFadden, Grant, Kemp, Vera |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694393/ https://www.ncbi.nlm.nih.gov/pubmed/33167307 http://dx.doi.org/10.3390/biomedicines8110474 |
Ejemplares similares
-
Oncolytic Virotherapy with Myxoma Virus
por: Rahman, Masmudur M., et al.
Publicado: (2020) -
Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy
por: Rahman, Masmudur M., et al.
Publicado: (2021) -
Oncolytic Virus-Mediated RAS Targeting in Rhabdomyosarcoma
por: Phelps, Michael P., et al.
Publicado: (2018) -
Oncolytic Viruses and the Immune System: The Dynamic Duo
por: Lemos de Matos, Ana, et al.
Publicado: (2020) -
Oncolytic Virotherapy for Hematological Malignancies
por: Bais, Swarna, et al.
Publicado: (2012)